サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1576088

変形性関節症治療薬の世界市場の評価：解剖学的構造別、薬剤タイプ別、薬剤クラス別、投与経路別、地域別、機会、予測（2017年～2031年）

Osteoarthritis Therapeutics Market Assessment, By Anatomy, By Drug Type, By Drug Class, By Route of Administration, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 238 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
変形性関節症治療薬の世界市場の評価：解剖学的構造別、薬剤タイプ別、薬剤クラス別、投与経路別、地域別、機会、予測（2017年～2031年）
出版日: 2024年10月24日
発行: Market Xcel - Markets and Data
ページ情報: 英文 238 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の変形性関節症治療薬の市場規模は、2023年の80億7,000万米ドルから2031年に158億5,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで8.80％の成長が見込まれます。市場は、先進の治療オプションの重視に加え、疾病負担の増大の影響を受けて成長を続けると予測されます。

市場は、特に老年人口で有病率が増加しているため、急速に拡大しています。効果的な疼痛管理オプションに対する需要が、非侵襲および低侵襲の治療法を含む治療法の革新を後押ししています。進行中の疾患修飾治療に関する研究は、患者に持続的な緩和と関節機能の向上をもたらすことを目的としたもので、今後の市場拡大が予測されます。この市場にとっての主な課題は、医薬品に伴う副作用や治療期間の長期化などです。しかし、規制当局の承認や新薬の上市に伴い、市場は促進要因のもとで活況を呈しています。例えば2024年3月、Pacira BioSciencesは、同社の遺伝子治療製品候補であるPCRX-201が、変形性膝関節症の治療薬としてFDA（米国食品医薬品局）からRMAT指定を受けたと発表しました。これは、有望な第1相試験データに裏打ちされた、この分野で初めての遺伝子治療薬です。

当レポートでは、世界の変形性関節症治療薬市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の変形性関節症治療薬市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 解剖学的構造別
    • 薬剤タイプ別
    • 薬剤クラス別
    • 投与経路別
    • 流通チャネル別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • 解剖学的構造別
    • 薬剤タイプ別
    • 薬剤クラス別
    • 投与経路別
    • 流通チャネル別
    • 地域別

第5章 北米の変形性関節症治療薬市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 解剖学的構造別
    • 薬剤タイプ別
    • 薬剤クラス別
    • 投与経路別
    • 流通チャネル別
    • シェア：国別
  • 各国の市場の評価
    • 米国の変形性関節症治療薬市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州の変形性関節症治療薬市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋の変形性関節症治療薬市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の変形性関節症治療薬市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの変形性関節症治療薬市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

  • 市場促進要因
  • 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Pfizer Inc
    • Bayer AG
    • Anika Therapeutics, Inc.
    • Bioventus Inc.
    • Ferring Pharmaceuticals Inc.
    • Assertio Holdings, Inc.
    • Novartis AG
    • Eli Lilly and Company

第21章 戦略的推奨

第22章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 3. Global Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 4. Global Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 5. Global Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Osteoarthritis Therapeutics Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 8. North America Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 9. North America Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 10. North America Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 11. North America Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 12. North America Osteoarthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 14. United States Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 15. United States Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 16. United States Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 17. United States Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 18. Canada Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Canada Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 20. Canada Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 21. Canada Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 22. Canada Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 23. Mexico Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Mexico Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 25. Mexico Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 26. Mexico Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 27. Mexico Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 28. Europe Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Europe Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 30. Europe Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 31. Europe Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 32. Europe Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 33. Europe Osteoarthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Germany Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 36. Germany Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 37. Germany Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 38. Germany Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 39. France Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. France Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 41. France Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 42. France Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 43. France Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Italy Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Italy Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 46. Italy Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 47. Italy Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 48. Italy Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 49. United Kingdom Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. United Kingdom Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 51. United Kingdom Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 52. United Kingdom Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 53. United Kingdom Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 54. Russia Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 55. Russia Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 56. Russia Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 57. Russia Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 58. Russia Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 59. Netherlands Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Netherlands Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 61. Netherlands Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 62. Netherlands Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 63. Netherlands Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 64. Spain Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Spain Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 66. Spain Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 67. Spain Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 68. Spain Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69. Turkey Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Turkey Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 71. Turkey Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 72. Turkey Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 73. Turkey Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74. Poland Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Poland Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 76. Poland Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 77. Poland Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 78. Poland Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 79. South America Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 80. South America Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 81. South America Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 82. South America Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 83. South America Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 84. South America Osteoarthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. Brazil Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 87. Brazil Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 88. Brazil Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 89. Brazil Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 90. Argentina Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Argentina Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 92. Argentina Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 93. Argentina Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 94. Argentina Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 95. Asia-Pacific Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 97. Asia-Pacific Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 98. Asia-Pacific Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 99. Asia-Pacific Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 100. Asia-Pacific Osteoarthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 101. India Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. India Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 103. India Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 104. India Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 105. India Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106. China Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. China Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 108. China Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 109. China Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 110. China Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 111. Japan Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 112. Japan Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 113. Japan Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 114. Japan Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 115. Japan Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 116. Australia Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 117. Australia Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 118. Australia Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 119. Australia Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 120. Australia Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 121. Vietnam Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Vietnam Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 123. Vietnam Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 124. Vietnam Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 125. Vietnam Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 126. South Korea Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. South Korea Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 128. South Korea Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 129. South Korea Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 130. South Korea Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. Indonesia Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Indonesia Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 133. Indonesia Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 134. Indonesia Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Indonesia Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Philippines Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 137. Philippines Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 138. Philippines Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 139. Philippines Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 140. Philippines Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 141. Middle East & Africa Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 143. Middle East & Africa Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 144. Middle East & Africa Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 145. Middle East & Africa Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 146. Middle East & Africa Osteoarthritis Therapeutics Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 149. Saudi Arabia Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 150. Saudi Arabia Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 151. Saudi Arabia Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 152. UAE Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 153. UAE Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 154. UAE Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 155. UAE Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 156. UAE Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 157. South Africa Osteoarthritis Therapeutics Market, By Value, In USD Billion, 2017-2031F
  • Figure 158. South Africa Osteoarthritis Therapeutics Market Share (%), By Anatomy, 2017-2031F
  • Figure 159. South Africa Osteoarthritis Therapeutics Market Share (%), By Drug Type, 2017-2031F
  • Figure 160. South Africa Osteoarthritis Therapeutics Market Share (%), By Drug Class, 2017-2031F
  • Figure 161. South Africa Osteoarthritis Therapeutics Market Share (%), By Route of Administration, 2017-2031F
  • Figure 162. By Anatomy Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX12135

Global osteoarthritis therapeutics market is projected to witness a CAGR of 8.80% during the forecast period 2024-2031, growing from USD 8.07 billion in 2023 to USD 15.85 billion in 2031. The market for osteoarthritis treatment is anticipated to keep growing under the influence of the growing disease burden, along with the heightened emphasis on advanced treatment options.

Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, stiffness, and reduced mobility. It commonly affects weight-bearing joints such as knees and hips. Therapeutic approaches include lifestyle modifications such as exercise and weight management, pharmacological treatments such as analgesics and anti-inflammatories, and interventional therapies such as corticosteroid injections or viscosupplementation. In severe cases, surgical options, such as joint replacement, may be considered. The osteoarthritis therapeutic market is expanding rapidly due to the rising prevalence of the condition, particularly among aging populations. Demand for effective pain management options drives innovation in treatment modalities, including non-invasive and minimally invasive therapies. Ongoing research into disease-modifying treatments holds promise for future market expansion, aiming to provide lasting relief and improved joint function for affected individuals. The major challenges for this market include side effects associated with medicines and longer duration of treatment. However, the market thrives under driving forces coupled with regulatory approvals and drug launches. For instance, in March 2024, Pacira BioSciences announced that its gene therapy product candidate, PCRX-201, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the Food and Drug Administration (FDA) for treating knee osteoarthritis. This marks the first gene therapy to achieve such designation in this area, supported by promising Phase 1 trial data.

Increasing Burden of Osteoarthritis to Create Demand for Therapeutics

An upsurge in the burden of osteoarthritis is expected to propel the demand for osteoarthritis therapeutics products. The aging population and increase in obesity rates lead to the prevalence of osteoarthritis rising steadily, especially among the older population. Higher awareness and better diagnostic techniques help patients visit hospitals at earlier stages and, thus, increase the therapeutic demand. Health care expenditure in this case tends to be higher. Therefore, the increased availability of these therapies will result in further research and development into innovative treatments targeting the disease at its root mechanism. Treatment personalization is being improved because of a shift towards more patient-centric approaches, alongside regulatory support for new therapies, to increase patient outcomes. For instance, according to an article published in The Lancet Rheumatology in September 2023, there will be an estimated 642 million individuals with knee osteoarthritis, 279 million individuals with hand osteoarthritis, 62.6 million individuals with hip osteoarthritis, and 118 million individuals with other types of osteoarthritis by 2050.

Advancements in Pain Therapeutics to Drive Market Growth

Recent developments in osteoarthritic pain therapeutics have greatly transformed the osteoarthritis therapeutics market. Wherein conventional drug development has concentrated mainly on providing relief of pain via the use of drugs, such as NSAIDs and corticosteroids, whilst new therapies target osteoarthritis pathophysiology. Among these emerging agents, biologics, such as monoclonal antibodies and gene therapies targeting specific inflammatory pathways, give way to more personalized and effective options for treatment. Approaches through regenerative medicine will include stem cell therapy and platelet-rich plasma injections. These are expected to further add to the patient's therapeutic options and, in the final analytical play, quality of life while changing the competitive landscape in the osteoarthritis therapeutics market. For instance, in November 2023, the University of Miami secured FDA approval for a groundbreaking study on genicular artery embolization (GAE) as a treatment for knee osteoarthritis. This minimally invasive procedure aims to reduce pain and inflammation, with patients reporting significant pain relief within a week. The study will be the first of its kind in South Florida, addressing a critical need for effective non-surgical options.

Viscosupplementation Agents to Dominate Market Share

The segment of viscosupplementation agents holds the leading market share of osteoarthritis therapeutics based on several compelling grounds, owing to targeted pain relief through restored viscosity of the synovial fluid, thereby enhancing joint lubrication and reducing friction. This mechanism is directly aimed at one of the primary actions of osteoarthritis, hence favored by patients and healthcare providers. Further, the rising prevalence of osteoarthritis, particularly in elderly populations, increases the need for safe, non-pharmacological interventions. Local therapies, such as viscosupplementation, are generally preferred over systemic drugs due to their local action and fewer systemic side effects. The advancement in formulation technology has improved the efficacy and extended duration of viscosupplementation treatment, which will contribute to market growth. Furthermore, innovative product launches from market players enhance the growth rate of the market. For instance, in February 2024, IBSA PHARMA LIMITED in the United Kingdom launched the SINOVIAL range, an innovative treatment for musculoskeletal conditions, particularly osteoarthritis. This advanced viscosupplementation product combines high and low molecular weight hyaluronic acid, enhancing joint lubrication and reducing pain. It aims to fill the treatment gap between conservative care and surgery, improving the quality of life for approximately 10 million arthritis patients in the United Kingdom.

North America to Dominate the Osteoarthritis Therapeutics Market Share

North America leads the share of the osteoarthritis therapeutics market as mostly the prevalence of the disease is at an all-time high due to the rate of obesity in people, thus requiring effective treatment. A developed healthcare infrastructure goes along with thorough research and development works that encourage innovation in osteoarthritis therapies, including pharmaceuticals and biologics. Furthermore, investments from pharmaceutical companies make more varied treatments possible-from pain management to joint injections. In addition, the FDA in North America supports the approval of new therapeutics, thus ensuring timely access to cutting-edge treatments. Lastly, the presence of a solid framework for insurance often means full or partial coverage of treatment costs for osteoarthritis. For instance, in April 2024, Paradigm Biopharmaceuticals Ltd. submitted essential documents to the USFDA to advance its Phase 3 trial for injectable pentosan polysulfate sodium (iPPS/Zilosul) aimed at treating osteoarthritis. This submission includes data from five nonclinical studies and a successful Phase 2 trial, with plans to begin enrollment in late 2024. The company anticipates FDA feedback within three months, potentially expediting its clinical development process.

Future Market Scenario (2024 - 2031F)

One area of transformation in the therapeutic osteoarthritis market is introducing a treatment via MedTech devices such as Apos. Clinically approved to reduce knee pain, Apos was launched in March 2024 and has been endorsed for the MedTech Funding Mandate by the National Health Service (NHS). This can lead to a smoother and faster route to effective treatments without waiting for the patient's plight to be addressed. Cost efficiency built into this device reduces patients' surgical interventions while improving their results, avoiding 74% of surgeries. The incorporation of such technologies is indicative of a broader trend towards value-based healthcare, which moves increasingly towards a more patient-centered approach, besides an improved quality of life. Apos is one of the exemplary illustrations of how innovative solutions can help address inadequacies well inherent within often non-standardized existing treatment pathways. However, healthcare systems progressing into a strong emphasis on efficiency, patient satisfaction, and advanced therapeutic options, including Apos, are probably going to be the driving factors toward future growth in the osteoarthritis market, where eventually, noninvasive treatments are going to be at its core. This marks a very promising horizon for patients and providers alike.

Key Players Landscape and Outlook

The medication available for osteoarthritis includes generic and branded medicines. Notable pharmaceutical companies are marketing the branded medicines while various local and global players provide generic drugs and analgesics, making the market slightly dynamic. Recent market activities include regulatory proceedings and announcements for business initiatives.

In September 2024, Sun Pharmaceutical Industries Limited and Israel-based Moebius Medical Limited received fast-track designation from the USFDA for their non-opioid therapy MM-II, aimed at treating osteoarthritis knee pain. This designation allows for expedited review and potentially accelerated approval. The companies plan to initiate Phase 3 clinical trials and seek a CE Mark in the European Union.

In April 2024, Crescent Innovations, Inc. announced the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis treatments, along with various intellectual property and know-how assets. PgGA was developed as the next generation of viscosupplements for treating degenerative joint disease. Unlike the current state-of-the-art osteoarthritis treatment, hyaluronic acid, PgGA has tripled the charge density, making it unique in its properties. Crescent Innovations has demonstrated, both in vitro and in vivo, that PgGA can significantly reduce matrix metalloproteinases (MMPs) and other inflammatory markers compared to hyaluronic acid.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Osteoarthritis Therapeutics Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Anatomy
      • 4.2.1.1. Knee Osteoarthritis
      • 4.2.1.2. Hip Osteoarthritis
      • 4.2.1.3. Hand Osteoarthritis
      • 4.2.1.4. Others
    • 4.2.2. By Drug Type
      • 4.2.2.1. Prescription Drugs
      • 4.2.2.2. Over-the-counter Drugs
    • 4.2.3. By Drug Class
      • 4.2.3.1. Viscosupplementation Agents
      • 4.2.3.2. Nonsteroidal Anti-inflammatory Drugs
        • 4.2.3.2.1. Naproxen
        • 4.2.3.2.2. Aspirin
        • 4.2.3.2.3. Diclofenac
        • 4.2.3.2.4. Ibuprofen
        • 4.2.3.2.5. Other NSAIDs
      • 4.2.3.3. Analgesics
        • 4.2.3.3.1. Duloxetine
        • 4.2.3.3.2. Acetaminophen
      • 4.2.3.4. Corticosteroids
      • 4.2.3.5. Others
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Parenteral
      • 4.2.4.3. Topical
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital and Clinics
      • 4.2.5.2. Retail Pharmacies
      • 4.2.5.3. Online Pharmacies
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Anatomy
    • 4.3.2. By Drug Type
    • 4.3.3. By Drug Class
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Osteoarthritis Therapeutics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Anatomy
      • 5.2.1.1. Knee Osteoarthritis
      • 5.2.1.2. Hip Osteoarthritis
      • 5.2.1.3. Hand Osteoarthritis
      • 5.2.1.4. Others
    • 5.2.2. By Drug Type
      • 5.2.2.1. Prescription Drugs
      • 5.2.2.2. Over-the-counter Drugs
    • 5.2.3. By Drug Class
      • 5.2.3.1. Viscosupplementation Agents
      • 5.2.3.2. Nonsteroidal Anti-inflammatory Drugs
        • 5.2.3.2.1. Naproxen
        • 5.2.3.2.2. Aspirin
        • 5.2.3.2.3. Diclofenac
        • 5.2.3.2.4. Ibuprofen
        • 5.2.3.2.5. Other NSAIDs
      • 5.2.3.3. Analgesics
        • 5.2.3.3.1. Duloxetine
        • 5.2.3.3.2. Acetaminophen
      • 5.2.3.4. Corticosteroids
      • 5.2.3.5. Others
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Parenteral
      • 5.2.4.3. Topical
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital and Clinics
      • 5.2.5.2. Retail Pharmacies
      • 5.2.5.3. Online Pharmacies
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Osteoarthritis Therapeutics Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Anatomy
          • 5.3.1.2.1.1. Knee Osteoarthritis
          • 5.3.1.2.1.2. Hip Osteoarthritis
          • 5.3.1.2.1.3. Hand Osteoarthritis
          • 5.3.1.2.1.4. Others
        • 5.3.1.2.2. By Drug Type
          • 5.3.1.2.2.1. Prescription Drugs
          • 5.3.1.2.2.2. Over-the-counter Drugs
        • 5.3.1.2.3. By Drug Class
          • 5.3.1.2.3.1. Viscosupplementation Agents
          • 5.3.1.2.3.2. Nonsteroidal Anti-inflammatory Drugs
          • 5.3.1.2.3.2.1. Naproxen
          • 5.3.1.2.3.2.2. Aspirin
          • 5.3.1.2.3.2.3. Diclofenac
          • 5.3.1.2.3.2.4. Ibuprofen
          • 5.3.1.2.3.2.5. Other NSAIDs
          • 5.3.1.2.3.3. Analgesics
          • 5.3.1.2.3.3.1. Duloxetine
          • 5.3.1.2.3.3.2. Acetaminophen
          • 5.3.1.2.3.4. Corticosteroids
          • 5.3.1.2.3.5. Others
        • 5.3.1.2.4. By Route of Administration
          • 5.3.1.2.4.1. Oral
          • 5.3.1.2.4.2. Parenteral
          • 5.3.1.2.4.3. Topical
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital and Clinics
          • 5.3.1.2.5.2. Retail Pharmacies
          • 5.3.1.2.5.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Osteoarthritis Therapeutics Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Osteoarthritis Therapeutics Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Osteoarthritis Therapeutics Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Osteoarthritis Therapeutics Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Sanofi S.A.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. GlaxoSmithKline plc
    • 20.3.3. Pfizer Inc
    • 20.3.4. Bayer AG
    • 20.3.5. Anika Therapeutics, Inc.
    • 20.3.6. Bioventus Inc.
    • 20.3.7. Ferring Pharmaceuticals Inc.
    • 20.3.8. Assertio Holdings, Inc.
    • 20.3.9. Novartis AG
    • 20.3.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer